MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Personalis DPO Ratio 2011-2026 | PSNL
Annual DPO Ratio Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.3 | 91.7 | 77.9 | 59.4 | 48.8 | 62.1 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.7 | 48.8 | 67.9 |
Quarterly DPO Ratio Personalis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.4 | 65.4 | 48.7 | - | 60.2 | 60 | 78.4 | - | 55 | 75.8 | 76.8 | - | 39.8 | 40.1 | 89.6 | - | 52.1 | 52.2 | 50.3 | - | 52.3 | 51.1 | 47.2 | - | 58.1 | 67.5 | 62.9 | - | 83.5 | 46.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 89.6 | 39.8 | 60.4 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M |  USA |
 |
Co-Diagnostics
CODX
|
106 | $ 5.87 | -1.92 % | $ 172 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 24.15 | 3.0 % | $ 258 M |  China |
 |
Castle Biosciences
CSTL
|
52 | $ 38.99 | -1.69 % | $ 1.08 B | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
70.4 | $ 69.06 | -2.7 % | $ 26.7 B | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.57 | -1.26 % | $ 2 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
83.6 | $ 105.42 | -2.0 % | $ 12.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
Illumina
ILMN
|
56.3 | $ 148.72 | 2.18 % | $ 23.6 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 20.22 | -1.73 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 237.39 | -0.69 % | $ 174 B | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 243.08 | 0.85 % | $ 44.1 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 12.33 | 5.61 % | $ 350 M |  Israel |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.12 | -1.22 % | $ 101 K | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 65.51 | -2.92 % | $ 4.53 B | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 102.24 | - | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 28.35 | 0.67 % | $ 857 M | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 618.21 | 3.17 % | $ 19.1 B | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
42 | $ 6.65 | 1.14 % | $ 602 M | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 20.52 | 0.44 % | $ 504 M | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 225.43 | 3.02 % | $ 11.6 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
Natera
NTRA
|
17.9 | $ 234.04 | -0.6 % | $ 23 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 497.61 | 0.35 % | $ 31.8 B |  Schweiz |
 |
OPKO Health
OPK
|
43.1 | $ 1.33 | -0.38 % | $ 923 M | USA |
 |
ENDRA Life Sciences
NDRA
|
1.65 K | $ 4.37 | -3.12 % | $ 2.35 M | USA |
 |
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | USA |
 |
Neogen Corporation
NEOG
|
62.7 | $ 9.26 | -1.17 % | $ 2.01 B | USA |
 |
Pacific Biosciences of California
PACB
|
33.5 | $ 2.13 | 6.01 % | $ 540 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 177.08 | 1.15 % | $ 19.7 B | USA |
 |
Organovo Holdings
ONVO
|
82.9 K | - | -2.3 % | $ 19.4 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 251.0 | 0.24 % | $ 21.1 B | USA |